Sarepta Therapeutics (SRPT) Misses Q4 EPS by 7c, Revenue Misses

Sarepta Therapeutics (NASDAQ: SRPT) reported Q4 EPS of ($1.84), $0.07 worse than the analyst estimate of ($1.77). Revenue for the quarter came in at $122.6 million versus the consensus estimate of $146.3 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• SPS Commerce hires Morgan Stanley to explore sale amid activist push - Reuters
• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance